{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:07:32Z","timestamp":1778825252093,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.05.003","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T20:04:29Z","timestamp":1778357069000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The gut microbiome: Recent findings and future opportunities in cystic fibrosis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3790-1721","authenticated-orcid":false,"given":"Ryan","family":"Marsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6708-3296","authenticated-orcid":false,"given":"James M","family":"Tricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7489-9205","authenticated-orcid":false,"given":"Laurence","family":"Delhaes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4767-6238","authenticated-orcid":false,"given":"Jennifer M","family":"Bomberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1101-4048","authenticated-orcid":false,"given":"Christopher","family":"van der Gast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jcf.2026.05.003_bib0001","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The human intestinal microbiome in health and disease","volume":"375","author":"Lynch","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcf.2026.05.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s41030-025-00303-4","article-title":"Impact of CFTR modulators on longitudinal cystic fibrosis survival and mortality: review and secondary analysis","author":"Rubin","year":"2025","journal-title":"Pulm Ther."},{"issue":"7","key":"10.1016\/j.jcf.2026.05.003_bib0003","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17476348.2023.2228194","article-title":"Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis","volume":"17","author":"Yule","year":"2023","journal-title":"Expert Rev Respir Med"},{"issue":"8","key":"10.1016\/j.jcf.2026.05.003_bib0004","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113754","article-title":"Use of microbiome analysis as a complementary endpoint in clinical trials","volume":"28","author":"Velo-Suarez","year":"2025","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.jcf.2026.05.003_bib0006","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41579-022-00768-z","article-title":"Microbiota succession throughout life from the cradle to the grave","volume":"20","author":"Martino","year":"2022","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.003_bib0007","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.chom.2015.04.004","article-title":"Dynamics and stabilization of the human gut microbiome during the first year of life","volume":"17","author":"B\u00e4ckhed","year":"2015","journal-title":"Cell Host & Microbe"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.003_bib0008","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41396-019-0553-2","article-title":"Breast milk-derived human milk oligosaccharides promote Bifidobacterium interactions within a single ecosystem","volume":"14","author":"Lawson","year":"2020","journal-title":"The ISME J"},{"key":"10.1016\/j.jcf.2026.05.003_bib0009","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.immuni.2019.02.014","article-title":"A weaning reaction to microbiota is required for resistance to immunopathologies in the adult","volume":"50","author":"Al Nabhani","year":"2019","journal-title":"Immunity"},{"issue":"7410","key":"10.1016\/j.jcf.2026.05.003_bib0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nature11319","article-title":"Gut microbiota composition correlates with diet and health in the elderly","volume":"488","author":"Claesson","year":"2012","journal-title":"Nature"},{"issue":"50","key":"10.1016\/j.jcf.2026.05.003_bib0011","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2316579120","article-title":"Gut dysbiosis: Ecological causes and causative effects on human disease","volume":"120","author":"Winter","year":"2023","journal-title":"Proc Natl Acad Sci"},{"issue":"49","key":"10.1016\/j.jcf.2026.05.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2411919121","article-title":"Global trends in antibiotic consumption during 2016\u20132023 and future projections through 2030","volume":"121","author":"Klein","year":"2024","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.jcf.2026.05.003_bib0013","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/gutjnl-2019-320204","article-title":"Interaction between drugs and the gut microbiome","volume":"69","author":"Weersma","year":"2020","journal-title":"Gut"},{"issue":"22","key":"10.1016\/j.jcf.2026.05.003_bib0014","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1128\/AEM.05933-11","article-title":"Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings","volume":"77","author":"Duytschaever","year":"2011","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.003_bib0015","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s10620-022-07812-1","article-title":"Cystic fibrosis-related gut dysbiosis: a systematic review","volume":"68","author":"Caley","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.003_bib0016","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41591-019-0714-x","article-title":"Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure","volume":"26","author":"Hayden","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03420-24","article-title":"Persistent delay in maturation of the developing gut microbiota in infants with cystic fibrosis","volume":"16","author":"Verster","year":"2025","journal-title":"mBio"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02290-2023","article-title":"The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut\u2013lung axis","volume":"63","author":"Frayman","year":"2024","journal-title":"Eur Respirat J"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.003_bib0019","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jcf.2024.06.016","article-title":"Gut microbiota in adults with cystic fibrosis: Implications for the severity of the CFTR gene mutation and nutritional status","volume":"23","author":"Durda-Masny","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2026.05.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009753","article-title":"The cystic fibrosis intestine","volume":"3","author":"De Lisle","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0021","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcf.2021.11.014","article-title":"Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis","volume":"21","author":"Marsh","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100551","article-title":"Impaired intestinal free fatty acid transport followed by chylomicron malformation, not pancreatic insufficiency, cause metabolic defects in cystic fibrosis","volume":"65","author":"Teng","year":"2024","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.003_bib0023","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0021-9258(18)57092-7","article-title":"Rapid method for the determination of fat in feces","volume":"177","author":"Van de Kamer","year":"1949","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.003_bib0024","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/s41390-024-03209-0","article-title":"Faecal lipid profile as a new marker of fat maldigestion, malabsorption and microbiota","volume":"96","author":"Asensio-Grau","year":"2024","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jcf.2018.08.009","article-title":"Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis","volume":"18","author":"van de Peppel","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"12","key":"10.1016\/j.jcf.2026.05.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1266","article-title":"Diet-induced dysbiosis and genetic background synergize with cystic fibrosis transmembrane conductance regulator deficiency to promote cholangiopathy in mice","volume":"2","author":"Debray","year":"2018","journal-title":"Hepatology Commun"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0027","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jcf.2023.09.010","article-title":"Changes in fecal lipidome after treatment with ivacaftor without changes in microbiome or bile acids","volume":"23","author":"Bass","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0028","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jcf.2024.02.015","article-title":"Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Duong","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2026.05.003_bib0029","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","author":"Cheng","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2026.05.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01451-25","article-title":"Profiling bile acids in the stools of humans and animal models of cystic fibrosis","author":"Carmichael","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.003_bib0031","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12890-025-03621-0","article-title":"Sex disparities in cystic fibrosis in the era of highly effective modulator treatment","volume":"25","author":"McNally","year":"2025","journal-title":"BMC Pulmonary Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.003_bib0032","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcf.2024.05.002","article-title":"Impact of extended Elexacaftor\/Tezacaftor\/Ivacaftor therapy on the gut microbiome in cystic fibrosis","volume":"23","author":"Marsh","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.003_bib0033","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2156254","article-title":"Diet and the gut-lung axis in cystic fibrosis - direct & indirect links","volume":"15","author":"McKay","year":"2023","journal-title":"Gut Microbes"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.003_bib0035","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1073\/pnas.1714373115","article-title":"Adaptation of commensal proliferating Escherichia coli to the intestinal tract of young children with cystic fibrosis","volume":"115","author":"Matamouros","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.jcf.2026.05.003_bib0036","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1039\/D4FO00325J","article-title":"In vitro screening of the impact of dietary prebiotic components, probiotic strains, and their symbiotic combinations on colonic microbiota in children with cystic fibrosis","volume":"15","author":"Viteri-Echeverr\u00eda","year":"2024","journal-title":"Food Funct"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.003_bib0037","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clnu.2024.09.036","article-title":"The impact of a whole foods dietary intervention on gastrointestinal symptoms, inflammation, and fecal microbiota in pediatric patients with cystic fibrosis: a pilot study","volume":"43","author":"Green","year":"2024","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.003_bib0038","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00046-23","article-title":"Development of the intestinal microbiome in cystic fibrosis in early life","volume":"8","author":"Price","year":"2023","journal-title":"mSphere"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.003_bib0039","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/jpn3.12389","article-title":"Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis","volume":"79","author":"Liu","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.003_bib0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12866-021-02305-z","article-title":"Infants with cystic fibrosis have altered fecal functional capacities with potential clinical and metabolic consequences","volume":"21","author":"Eng","year":"2021","journal-title":"BMC Microbiol"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.003_bib0041","article-title":"Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Reports"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.003_bib0042","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcf.2020.12.002","article-title":"Changes in fecal microbiota with CFTR modulator therapy: a pilot study","volume":"20","author":"Pope","year":"2021","journal-title":"J Cystic Fibrosis"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01175-23","article-title":"Tezacaftor\/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome","volume":"11","author":"Marsh","year":"2023","journal-title":"Microbiol Spectrum"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.003_bib0044","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01935-23","article-title":"Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor","volume":"15","author":"Reasoner","year":"2024","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64218-z","article-title":"CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial","volume":"16","author":"Knoll","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.003_bib0046","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2025.05.006","article-title":"Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor\/tezacaftor\/ivacaftor: Findings from the promise study","volume":"24","author":"Duong","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.003_bib0047","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcf.2023.12.004","article-title":"The gut microbiota in adults with cystic fibrosis compared to colorectal cancer","volume":"23","author":"Caley","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2026.05.003_bib0048","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/thoraxjnl-2020-216265","article-title":"Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials","volume":"77","author":"Keogh","year":"2022","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71024","article-title":"Effects of therapeutic antibiotic exposure on the oropharyngeal and fecal microbiota in infants with cystic fibrosis","volume":"60","author":"Hayden","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.003_bib0050","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41385-022-00564-1","article-title":"Microbiome-based interventions to modulate gut ecology and the immune system","volume":"15","author":"Hitch","year":"2022","journal-title":"Mucosal Immunol"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0051","article-title":"Effectiveness of probiotics, prebiotics, and symbiotic supplementation in cystic fibrosis patients: a systematic review and meta-analysis of clinical trials","volume":"61","author":"Cruz Mosquera","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"10.1016\/j.jcf.2026.05.003_bib0052","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12102059","article-title":"Fecal microbiota transplantation for recurrent clostridioides difficile infections in a cystic fibrosis child previously screen positive, inconclusive diagnosis (CFSPID): a case report","volume":"12","author":"Marsiglia","year":"2024","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0053","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jhep.2024.03.041","article-title":"Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice","volume":"81","author":"Bertolini","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.003_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03144-23","article-title":"Intestinal Bacteroides modulates inflammation, systemic cytokines, and microbial ecology via propionate in a mouse model of cystic fibrosis","volume":"15","author":"Price","year":"2024","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1152\/physiolgenomics.00077.2023","article-title":"Fecal dysbiosis and inflammation in intestinal-specific Cftr knockout mice on regimens preventing intestinal obstruction","volume":"56","author":"Young","year":"2024","journal-title":"Physiol Genom"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1128\/jb.00286-23","article-title":"An in vitro medium for modeling gut dysbiosis associated with cystic fibrosis","volume":"206","author":"Barrack","year":"2024","journal-title":"J Bacteriol"},{"issue":"9","key":"10.1016\/j.jcf.2026.05.003_bib0057","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41575-022-00605-x","article-title":"The gut microbiome as a modulator of healthy ageing","volume":"19","author":"Ghosh","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.003_bib0058","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(18)30188-8","article-title":"Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"19","author":"Yamada","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.003_bib0059","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13073-020-0710-2","article-title":"Interactions between the gut microbiome and host gene regulation in cystic fibrosis","volume":"12","author":"Dayama","year":"2020","journal-title":"Genome Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.003_bib0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jpn3.12350","article-title":"Premodulator microbiome alterations associated with postmodulator growth outcomes in pediatric cystic fibrosis: can we predict outcomes?","volume":"79","author":"Sanville","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326001098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326001098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:13:35Z","timestamp":1778822015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326001098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":60,"alternative-id":["S1569199326001098"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The gut microbiome: Recent findings and future opportunities in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}